Vetoquinol operates as a diversified player in the global veterinary pharma market with products spanning pain/inflammation, antibiotics, anti-parasites, dermatology, cardiology, and behavior management. The company's geographic diversification—Europe 48.9%, North America 35.7%, Asia-Pacific 15.4%—and portfolio spanning 5 production sites globally provides operational resilience and market penetration advantages.
Cyborg Score Rationale
Vetoquinol demonstrates stable operations with consistent €520M+ revenue, global distribution across 100+ countries, and presence in growing pet pharma segments. However, modest organic growth (0.2% constant currency in 2025), mid-market capitalization of ~€922M, and exposure to competitive veterinary pharma markets present moderate headwinds.
Top Insights
Pet products represent 70% of sales—capturing tailwinds in premium pet healthcare spending and humanization of pet care
Essential Products segment grew 4.1% at constant exchange rates in 2025, demonstrating product portfolio resilience
Geographic diversification across Americas (35.7%), Europe (48.9%), and Asia-Pacific (15.4%) reduces single-market risk
Buyback programs announced in January 2026 signal confidence in valuation and capital return to shareholders
Named Competitors
Animal health division — Global veterinary pharma leader and primary competitor
Veterinary pharmaceuticals — Major animal health division competitor
Companion animal products — Significant player in pet and livestock segments
Recent Developments
(January 2026) Monthly voting rights disclosure and buyback program announcements
(February 2026) 2025 annual results released with €526M revenue
(January 2026) Continued share buyback programs under active management
Open the full interactive Vetoquinol SA report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.